Charles River Laboratories (CRL) stock soared 5.24% in Monday's intraday trading session. The rise appears to be driven by positive research updates from analysts covering the company.
According to TD Cowen, the firm cut its price target on CRL to $179 from $182 but maintained a Hold rating on the stock. The adjustment followed Charles River's recent financial results and likely factors in the analysts' updated outlook for the company.
Additionally, broader market sentiment towards Charles River Laboratories seems favorable, as evidenced by the news roundup highlighting various analysts raising their ratings and price targets on the stock. The positive analyst views suggest optimism around CRL's growth prospects and potential earnings performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.